病毒|战疫过程“全覆盖”，抗新冠病毒的单克隆中和抗体到底是何方神圣？6000字长文深度解析丨奇点深度( 五 ) 血浆|细胞|深度|长文|研究|抗体

在抗病毒领域，单克隆中和抗体作为一种能够快速获得，且能用于传染病治疗和预防的药物，展现了它抗疫“多面手”的特质。

文章图片

▲ 单克隆中和抗体可以用于新冠防治的多个阶段
可以想见，在人类抗击新冠疫情的过程中，单克隆中和抗体会成为新冠疫苗有力的补充，同时与小分子抗病毒药物一起让更多的患者免于住院或死亡，并给使用者提供长期的免疫保护。
参考文献：
[1].Behring E. Ueber das zustandekommen der diphtherie-immunit?t und der tetanus-immunit?t bei thieren[J]. Drucke 19. Jh., 1890.
[2].https://www.nobelprize.org/prizes/medicine/1901/summary/
[5].https://www.nobelprize.org/prizes/medicine/1984/summary/
[6].https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-ebola-virus
[7].https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-ebola-virus
[9].Wang R, Zhang Q, Ge J, et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity. 2021;54(7):1611-1621.e5. doi:10.1016/j.immuni.2021.06.003
[10].Dougan M, Azizad M, Mocherla B, et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clin Infect Dis. 2021;ciab912. doi:10.1093/cid/ciab912
[13].Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2022;327(13):1236-1246. doi:10.1001/jama.2022.2832
[14].https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains
[19].https://mp.weixin.qq.com/s/48JorUncaQ_isz07rBpVPw
[20].https://www.who.int/news/item/22-02-2022-statement-on-omicron-sublineage-ba.2
[22].https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/nonhospitalized-adults--therapeutic-management/
[25].Case J B, Mackin S, Errico J, et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains[J]. bioRxiv, 2022.
[26].Zhang Y, Hao X, Ma J, et al. Phase 1 safety and pharmacokinetics studies of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies[J]. medRxiv, 2021.
[27]. ERA-EDTA Council; ERACODA Working Group. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2021;36(1):87-94. doi:10.1093/ndt/gfaa314
[28].Tregoning J S, Flight K E, Higham S L, et al. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape[J]. Nature Reviews Immunology, 2021, 21(10): 626-636.
[29].Levin E G, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months[J]. New England Journal of Medicine, 2021.
[30].Lin D Y, Gu Y, Wheeler B, et al. Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina[J]. New England Journal of Medicine, 2022.
[31].O’Brien M P, Forleo-Neto E, Musser B J, et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19[J]. New England Journal of Medicine, 2021, 385(13): 1184-1195.
[32].https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-prophylaxis-trial-met-primary-endpoint.html
[33].https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-regen-cov-monoclonal-antibody-therapy-post-exposure-prophylaxis-prevention-covid-19